OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

ATI Inc/  US01741R1023  /

NYSE
2024-05-10  10:10:00 PM Chg. -0.45 Volume Bid2:00:00 AM Ask2:00:00 AM Market Capitalization Dividend Y. P/E Ratio
60.73USD -0.74% 950,266
Turnover: 37.86 mill.		 59.00Bid Size: 100 97.28Ask Size: 100 7.56 bill.USD - 18.92
GlobeNewswire 05-09 TTM Technologies, Inc. Appoints Wajid Ali to Board of Directors
GlobeNewswire 05-07 Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 03-27 William & Mary Campus Mass Notification Drill Using ATI Systems’ Mass Notification Solution
GlobeNewswire 03-12 Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
GlobeNewswire 02-13 Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
GlobeNewswire 02-06 Seoul Robotics to Pursue Initial Public Offering with Samsung Securities as it Expands OEM Partnersh...
GlobeNewswire 01-25 Confluent Announces Significant Investment in ATI Nitinol Melt Expansion
GlobeNewswire 01-17 IBN Coverage Initiated for Astrotech Corp.
GlobeNewswire 01-16 Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
GlobeNewswire 2023-12-27 Eco Bright Future, Inc. Announces Signing of "Letter-of-Intent" With United Heritage, Sociedad Anoni...
GlobeNewswire 2023-12-12 Astrotech Announces Exciting New Technology Application and Introduces New Subsidiary
GlobeNewswire 2023-12-05 American Trust Insurance Joins World Insurance Associates
GlobeNewswire 2023-11-27 ATI Systems Honored with 2023 ‘ASTORS’ Homeland Security Award
GlobeNewswire 2023-11-13 Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (AT...
GlobeNewswire 2023-11-06 Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
GlobeNewswire 2023-10-27 Strategic Advisory Board Elevates sureti’s Property Claims Resolution Capabilities
GlobeNewswire 2023-10-25 Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT...
GlobeNewswire 2023-10-23 ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
GlobeNewswire 2023-10-19 Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV a...
GlobeNewswire 2023-10-03 Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic De...
GlobeNewswire 2023-09-30 ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
GlobeNewswire 2023-09-19 ATI PHYSICAL THERAPY INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti...
GlobeNewswire 2023-09-18 Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-21...
GlobeNewswire 2023-08-30 Churchill Franklin Automotive Launches Airbag Alert News Service
GlobeNewswire 2023-08-17 Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its Firs...